Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GMNN | O75496 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393403 | 1.00 | CYP1A2 (0.41) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL20581480 | 0.96 | ALDH1A1 (0.44) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL4362567 | 0.96 | ALDH1A1 (0.44) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL29124665 | 0.86 | CYP1A2 (0.40) | CYP1A2LMNAMAPK1MAPTGMNN | |
| SCHEMBL3044276 | 0.85 | LMNA (0.53) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL27650788 | 0.83 | LMNA (0.61) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2526939 | 0.82 | CYP1A2 (0.49) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL8947469 | 0.81 | MAPT (0.56) | ALDH1A1LMNAMAPK1MAPTFAAH | |
| SCHEMBL28623376 | 0.81 | LMNA (0.65) | CYP1A2ALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL12431977 | 0.81 | LMNA (0.65) | CYP1A2ALDH1A1LMNAMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2014-11-06 | — | — | US | claimed |
| US-20120071548-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | claimed |
| US-20040266872-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | BTG INTERNATIONAL LIMITED (GB) | 2004-12-30 | — | — | US | claimed |
| US-20010014696-A1 | Therapeutic compositions (II) | BTG INTERNATIONAL LIMITED (GB) | 2001-08-16 | — | — | US | claimed |
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | BTG INT LTD (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20130079406-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| US-20120071548-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-8101653-B2 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-7485743-B2 | Oligomeric ketone compounds | BTG INTERNATIONAL LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-6380244-B2 | USEFUL FOR SEIZURE CONTROL, METABOLIC DISEASE CONTROL, REDUCTION OF PROTEIN CATABOLISM, APPETITE SUPPRESSION, PARENTERAL NUTRITION, INCREASING CARDIAC EFFICIENCY, THERAPY OF DIABETES AND INSULIN RESISTANT STATES | METABOLIX, INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020013339-A1 | NUTRITIONAL AND THERAPEUTIC USES OF 3-HYDROXYALKANOATE OLIGOMERS | CJ CHEILJEDANG CORPORATION (KR) | 2002-01-31 | — | — | US | disclosed |
| US-6323237-B1 | NEURODEGENERATIVE DISORDER, MEMORY LOSS WITH AGING, INABILITY TO METABOLIZE GLUCOSE AND ENZYME INHIBITORS FOR PYRUVATE DEHYDROGENASE | BTG INTERNATIONAL LIMITED (GB) | 2001-11-27 | — | — | US | disclosed |
| US-20010041736-A1 | Therapy for nervous system disorders | BTG INTERNATIONAL LIMITED | 2001-11-15 | — | — | US | disclosed |
| US-20010014696-A1 | Therapeutic compositions (II) | BTG INTERNATIONAL LIMITED (GB) | 2001-08-16 | — | — | US | disclosed |
| EP-1098655-A2 | NUTRITIONAL AND THERAPEUTIC USES OF 3-HYDROXYALKANOATE OLIGOMERS | METABOLIX, INC. (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6207856-B1 | INSULIN RESISTANCE, CARDIAC EFFICIENCY, TREATING DISORDERS CAUSED BY DAMAGE TO BRAIN CELLS IN MEMORY, KETONE BODIES, POLYESTERS OF 3-HYDROXYBUTYRIC ACID | BTG INTERNATIONAL LIMITED (GB) | 2001-03-27 | — | — | US | disclosed |
| WO-2000004895-A2 | NUTRITIONAL AND THERAPEUTIC USES OF 3-HYDROXYALKANOATE OLIGOMERS | METABOLIX, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071548-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | CYP1A2 3678/4885ALDH1A1 1112/4885LMNA 437/4885 |
| US-20010014696-A1 | Therapeutic compositions (II) | CPT1B, GYS1, IAPP | CYP1A2 3501/4885ALDH1A1 1178/4885LMNA 394/4885 |
| US-20180098956-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, IAPP, GYS1 | CYP1A2 3778/4885ALDH1A1 1008/4885LMNA 433/4885 |
| US-20010041736-A1 | Therapy for nervous system disorders | GYS1, CPT1B, PYGB | CYP1A2 2579/4885ALDH1A1 1076/4885LMNA 665/4885 |
| US-20130079406-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, GYS1, IAPP | CYP1A2 3678/4885ALDH1A1 1112/4885LMNA 437/4885 |
| US-20040266872-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | CPT1B, BDNF, IAPP | CYP1A2 4419/4885ALDH1A1 672/4885LMNA 1150/4885 |
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, GYS1, IAPP | CYP1A2 3678/4885ALDH1A1 1112/4885LMNA 437/4885 |
| US-20020013339-A1 | NUTRITIONAL AND THERAPEUTIC USES OF 3-HYDROXYALKANOATE OLIGOMERS | HACD3, IAPP, HCN3 | CYP1A2 3600/4885ALDH1A1 3032/4885LMNA 3664/4885 |
| US-20090253781-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | CYP1A2 3678/4885ALDH1A1 1112/4885LMNA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.